

FINANCIAL TEAR SHEET

CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

PRIMARY IR CONTACT

Investor Relations
Phone: 647-479-9825
E-mail: ir@aptose.com

STOCK PERFORMANCE

APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	Can\$4.80
Change (%)	0.00 (0.00%)
Volume	6,658
52 Week Low	Can\$1.05
Market Cap	Can\$136,809,854
Rolling EPS	-0.82
PE Ratio	0
Shares Outstanding	28,502,053

Data as of March 19, 2018 9:33 a.m. ET



APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	\$3.64
Change (%)	▼ 0.03 (0.82%)
Volume	21,945
52 Week Low	\$0.78
Market Cap	\$104,602,535
Rolling EPS	-0.66
PE Ratio	0
Shares Outstanding	28,502,053

Data as of March 19, 2018 9:47 a.m. ET



RECENT PRESS RELEASES & UPCOMING EVENTS

March 15, 2018

Aptose to Present New CG'806 and APTO-253 Data at the 2018 AACR Annual Meeting

March 8, 2018

Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on

March 27, 2018

March 7, 2018

Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology

Date	Title
March 21, 2018 8:00 a.m. ET	Aptose Biosciences, Inc. at Oppenheimer 28th Annual Healthcare Conference
March 27, 2018 5:00 p.m. ET	Q4 2017 Aptose Biosciences, Inc. Earnings Conference Call

SEC FILINGS

Filing Date	Form
March 15, 2018	6-K
March 14, 2018	EFFECT
March 8, 2018	F-10/A
March 8, 2018	6-K

CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.